Details Basic Details Date Tuesday, August 21, 2018 Type Presentation Medical Product alemtuzumab daclizumab dalfampridine dimethyl fumarate fingolimod glatiramer acetate interferon beta-1A interferon beta-1B mitoxantrone natalizumab peginterferon beta-1a teriflunomide Materials Use of Multiple Sclerosis Drugs Among Live Birth Pregnancies in the United States Additional Information Information Host 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Abstracts of the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic, August 22–26, 2018 | Abstract 63 Sentinel Drug Study: Multiple Sclerosis (MS) Drugs & Exposure Before, During, and After Pregnancy Contributors Presenter(s) Danijela Stojanovic, Mayura Shinde, Nicole Haug, Mohamed Mohamoud, Leyla Sahin, Genna Panucci, Rajani Rajbhandari, Lockwood Taylor